Churg Strauss Syndrome

Brandon Hudgins Receives 2017 Rare Impact Award

The National Organization for Rare Disorders (NORD) today announced the people, organizations, and innovators who will be honored at the 2017 Rare Impact Awards on May 18 in Washington, D.C. The Rare Impact Awards is a charity event that celebrates those who are boldly leading efforts to make a difference…...

Read more

VF Board President Talks About Personal Impact of Vasculitis on Rare Disease Day 2017

VF Board President, Karen Hirsch, appeared on Good Morning Washington, WJLA in Washington D.C. to discuss the importance of raising awareness about all rare diseases on Rare Disease Day 2017.   Karen’s son, Michael, is a patient with GPA Wegener’s Vasculitis.   Karen’s message was that she knows from personal experience the…...

Read more

Introducing Dr. Jennifer Rodrigues – 2016-17 VCRC-VF Fellow

The Vasculitis Foundation welcomes Dr. Jennifer Rodrigues, as our 2016-2017 VCRC-VF Fellow.  Dr. Rodrigues completed medical school at the University of Calgary in 2011, her Internal Medicine training at McGill University in 2014, and a Nephrology fellowship at the University of Toronto this past year.  She will complete this fellowship…...

Read more

VF Partners with Northwestern University to Open Vasculitis Program

The Vasculitis Foundation and Northwestern Memorial Hospital’s Division of Rheumatology have launched the health system’s first Vasculitis Clinical Research Program. Vasculitis is an immune system disorder that causes destructive inflammation of the blood vessels, including arteries, veins, and capillaries. It is estimated about 1 in 3,300 people suffer from vasculitis.…...

Read more

Breakthrough Therapy for Patients with Giant Cell Arteritis

FDA Grants Breakthrough Therapy Designation for GENENTECH’S Actemra® (tocilizumab) in Giant Cell Arteritis, A form of vasculitis Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra® (tocilizumab) for giant…...

Read more